Many a U.S. pharma company has already completed an Irish tax inversion, picking up and moving overseas to take advantage of that country's lower rate. But plenty more are out there looking to follow suit–whether or not their targets like it. So what's a mid-sized Dublin-based drugmaker to do? Hire an adviser, if you're Shire.
written on 17.06.2014